<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221312</url>
  </required_header>
  <id_info>
    <org_study_id>H675-20192</org_study_id>
    <secondary_id>H675-20192-05</secondary_id>
    <secondary_id>39-62</secondary_id>
    <nct_id>NCT00221312</nct_id>
  </id_info>
  <brief_title>Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss</brief_title>
  <official_title>Alendronate to Prevent Perimenopausal Transition Bone Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine if Fosamax (alendronate), a medication approved by the Food and&#xD;
      Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal&#xD;
      women, is effective in decreasing the rate of bone loss which often begins to increase in the&#xD;
      three to five years preceding the menopause (perimenopausal transition).&#xD;
&#xD;
      During the three to five years prior to the menopause, the rate of bone loss increases. One&#xD;
      way that physicians treat this is with oral contraceptive medication. However, the incidence&#xD;
      of complications from oral contraceptives after the age of 40 increases. Therefore, a&#xD;
      non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a&#xD;
      class of compounds called bisphosphonates. This study is being done to determine whether&#xD;
      Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal&#xD;
      transition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">48</enrollment>
  <condition>Perimenopausal Bone Loss</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamax</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Perimenopausal women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ages 40-54 with symptomology of perimenopause including hot flashes, irregular&#xD;
             periods and vaginal dryness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women should not be on hormone replacements, oral contraceptives, or bone mineral&#xD;
             enhancing medications (bisphosphonates, selective estrogen receptor modulators&#xD;
             [SERM's], parathyroid hormone [PTH], calcitriol, fluorides)&#xD;
&#xD;
          -  They should not have any abnormalities of the esophagus which delay esophageal&#xD;
             emptying&#xD;
&#xD;
          -  They should not have hypocalcemia or severe kidney disease&#xD;
&#xD;
          -  Their bone mineral density (T-score) should not be greater than 2 standard deviations.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B. Jaffe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 5, 2008</last_update_submitted>
  <last_update_submitted_qc>May 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Jaffe, M.D.</name_title>
    <organization>UCaliforniaSF</organization>
  </responsible_party>
  <keyword>Perimenopausal bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

